Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

The SIRT6 Activator MDL-800 Inhibits PPARα and Fatty acid Oxidation-Related Gene Expression in Hepatocytes

  • Yeonsoo Kim (College of Pharmacy and Research Institute for Drug Development, Pusan National University) ;
  • Hyeokjin Lim (College of Pharmacy and Research Institute for Drug Development, Pusan National University) ;
  • Ye Eun Cho (College of Pharmacy and Research Institute for Drug Development, Pusan National University) ;
  • Seonghwan Hwang (College of Pharmacy and Research Institute for Drug Development, Pusan National University)
  • Received : 2024.12.30
  • Accepted : 2025.03.04
  • Published : 2025.05.01
Download PDF
⟨ Previous Next ⟩

Abstract

A histone deacetylase SIRT6 regulates the transcription of various genes involved in lipid metabolism. Fatty acid (FA) oxidation plays a pivotal role in maintaining hepatic lipid homeostasis, and its dysregulation significantly contributes to lipotoxicity and inflammation, driving the progression of steatotic liver disease. While SIRT6 is known to activate peroxisome proliferator-activated receptor-alpha (PPARα), a central regulator of FA oxidation, the development of SIRT6 activators capable of enhancing FA oxidation and mitigating steatotic liver disease has yet to be achieved. This study evaluated the effect of MDL-800, a selective SIRT6 activator, on the expression of PPARα and genes related to FA oxidation. In AML12 mouse hepatocytes, MDL-800 treatment activated SIRT6 but unexpectedly decreased the expression of PPARα and its FA oxidation-associated target genes. Furthermore, OSS128167, a selective SIRT6 inhibitor, did not reverse the suppressive effects of MDL-800 on PPARα, suggesting that MDL-800 downregulates PPARα and FA oxidation-related genes through a mechanism independent of SIRT6 activation. Mechanistic investigations revealed that MDL-800 increased the production of reactive oxygen species and activated stress kinases. The inhibition of PPARα by MDL-800 was reversed by co-treatment with the antioxidant N-acetylcysteine or the JNK inhibitor SP600125. In summary, MDL-800 suppresses PPARα and FA oxidation-related genes primarily through the induction of oxidative stress in hepatocytes, independent of its role as a SIRT6 activator.

Keywords

Acknowledgement

This work was supported by a 2-Year Research Grant of Pusan National University (S.H.). Figures were created with BioRender and published with the appropriate permission.

References

  1. Attucks, O. C., Jasmer, K. J., Hannink, M., Kassis, J., Zhong, Z., Gupta, S., Victory, S. F., Guzel, M., Polisetti, D. R., Andrews, R., Mjalli, A. M. and Kostura, M. J. (2014) Induction of heme oxygenase I (HMOX1) by HPP-4382: a novel modulator of Bach1 activity. PLoS One 9, e101044. https://doi.org/10.1371/journal.pone.0101044
  2. Carracedo, A., Cantley, L. C. and Pandolfi, P. P. (2013) Cancer metabolism: fatty acid oxidation in the limelight. Nat. Rev. Cancer 13, 227-232. https://doi.org/10.1038/nrc3483
  3. Cha, J. Y. and Repa, J. J. (2007) The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR. J. Biol. Chem. 282, 743-751. https://doi.org/10.1074/jbc.M605023200
  4. Cho, Y. E., Kim, Y., Kim, S. J., Lee, H. and Hwang, S. (2023) Overexpression of interleukin-8 promotes the progression of fatty liver to nonalcoholic steatohepatitis in mice. Int. J. Mol. Sci. 24, 15489.
  5. Chung, K. W., Cho, Y. E., Kim, S. J. and Hwang, S. (2022) Immunerelated pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis. Arch. Pharm. Res. 45, 229-244. https://doi.org/10.1007/s12272-022-01379-1
  6. Dong, X. C. (2023) Sirtuin 6-a key regulator of hepatic lipid metabolism and liver health. Cells 12, 663. https://doi.org/10.3390/cells12040663
  7. Elhanati, S., Ben-Hamo, R., Kanfi, Y., Varvak, A., Glazz, R., Lerrer, B., Efroni, S. and Cohen, H. Y. (2016) Reciprocal regulation between SIRT6 and miR-122 controls liver metabolism and predicts hepatocarcinoma prognosis. Cell Rep. 14, 234-242. https://doi.org/10.1016/j.celrep.2015.12.023
  8. Finck, B. N., Gropler, M. C., Chen, Z., Leone, T. C., Croce, M. A., Harris, T. E., Lawrence, J. C., Jr. and Kelly, D. P. (2006) Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/PPARalpha regulatory pathway. Cell Metab. 4, 199-210. https://doi.org/10.1016/j.cmet.2006.08.005
  9. Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M. and Sanyal, A. J. (2018) Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 24, 908-922. https://doi.org/10.1038/s41591-018-0104-9
  10. Geng, Y., Faber, K. N., de Meijer, V. E., Blokzijl, H. and Moshage, H. (2021) How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease? Hepatol. Int. 15, 21-35. https://doi.org/10.1007/s12072-020-10121-2
  11. Huang, Z., Zhao, J., Deng, W., Chen, Y., Shang, J., Song, K., Zhang, L., Wang, C., Lu, S., Yang, X., He, B., Min, J., Hu, H., Tan, M., Xu, J., Zhang, Q., Zhong, J., Sun, X., Mao, Z., Lin, H., Xiao, M., Chin, Y. E., Jiang, H., Xu, Y., Chen, G. and Zhang, J. (2018) Identification of a cellularly active SIRT6 allosteric activator. Nat. Chem. Biol. 14, 1118-1126. https://doi.org/10.1038/s41589-018-0150-0
  12. Hwang, S., Hartman, I. Z., Calhoun, L. N., Garland, K., Young, G. A., Mitsche, M. A., McDonald, J., Xu, F., Engelking, L. and DeBoseBoyd, R. A. (2016) Contribution of accelerated degradation to feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and cholesterol metabolism in the liver. J. Biol. Chem. 291, 13479-13494. https://doi.org/10.1074/jbc.M116.728469
  13. Hwang, S., He, Y., Xiang, X., Seo, W., Kim, S. J., Ma, J., Ren, T., Park, S. H., Zhou, Z., Feng, D., Kunos, G. and Gao, B. (2020a) Interleukin-22 ameliorates neutrophil-driven nonalcoholic steatohepatitis through multiple targets. Hepatology 72, 412-429. https://doi.org/10.1002/hep.31031
  14. Hwang, S., Wang, X., Rodrigues, R. M., Ma, J., He, Y., Seo, W., Park, S. H., Kim, S. J., Feng, D. and Gao, B. (2020b) Protective and detrimental roles of p38α mitogen-activated protein kinase in different stages of nonalcoholic fatty liver disease. Hepatology 72, 873-891. https://doi.org/10.1002/hep.31390
  15. Jiang, H., Khan, S., Wang, Y., Charron, G., He, B., Sebastian, C., Du, J., Kim, R., Ge, E., Mostoslavsky, R., Hang, H. C., Hao, Q. and Lin, H. (2013) SIRT6 regulates TNF-α secretion through hydrolysis of long-chain fatty acyl lysine. Nature 496, 110-113. https://doi.org/10.1038/nature12038
  16. Kim, H. S., Xiao, C., Wang, R. H., Lahusen, T., Xu, X., Vassilopoulos, A., Vazquez-Ortiz, G., Jeong, W. I., Park, O., Ki, S. H., Gao, B. and Deng, C. X. (2010) Hepatic-specific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis. Cell Metab. 12, 224-236. https://doi.org/10.1016/j.cmet.2010.06.009
  17. Kwon, Y. S., Cho, Y. E., Kim, Y., Koh, M. and Hwang, S. (2024) Dimethyloxalylglycine suppresses SREBP1c and lipogenic gene expressions in hepatocytes independently of HIF1A. Curr. Issues Mol. Biol. 46, 2386-2397. https://doi.org/10.3390/cimb46030151
  18. Liu, Z., Liu, W., Wang, W., Ma, Y., Wang, Y., Drum, D. L., Cai, J., Blevins, H., Lee, E., Shah, S., Fisher, P. B., Wang, X., Fang, X., Guo, C. and Wang, X. Y. (2023) CPT1A-mediated fatty acid oxidation confers cancer cell resistance to immune-mediated cytolytic killing. Proc. Natl. Acad. Sci. U. S. A. 120, e2302878120. https://doi.org/10.1073/pnas.2302878120
  19. Maity, S., Muhamed, J., Sarikhani, M., Kumar, S., Ahamed, F., Spurthi, K. M., Ravi, V., Jain, A., Khan, D., Arathi, B. P., Desingu, P. A. and Sundaresan, N. R. (2020) Sirtuin 6 deficiency transcriptionally upregulates TGF-β signaling and induces fibrosis in mice. J. Biol. Chem. 295, 415-434. https://doi.org/10.1074/jbc.RA118.007212
  20. Mehal, W. (2023) Mechanisms of liver fibrosis in metabolic syndrome. eGastroenterology 1, e100015. https://doi.org/10.1136/egastro-2023-100015
  21. Moon, Y. J., Zhang, Z., Bang, I. H., Kwon, O. K., Yoon, S. J., Kim, J. R., Lee, S., Bae, E. J. and Park, B. H. (2019) Sirtuin 6 in preosteoclasts suppresses age- and estrogen deficiency-related bone loss by stabilizing estrogen receptor α. Cell Death Differ. 26, 2358-2370. https://doi.org/10.1038/s41418-019-0306-9
  22. Moreno, M., Lombardi, A., Silvestri, E., Senese, R., Cioffi, F., Goglia, F., Lanni, A. and de Lange, P. (2010) PPARs: nuclear receptors controlled by, and controlling, nutrient handling through nuclear and cytosolic signaling. PPAR Res. 2010, 435689. https://doi.org/10.1155/2010/435689
  23. Naiman, S., Huynh, F. K., Gil, R., Glick, Y., Shahar, Y., Touitou, N., Nahum, L., Avivi, M. Y., Roichman, A., Kanfi, Y., Gertler, A. A., Doniger, T., Ilkayeva, O. R., Abramovich, I., Yaron, O., Lerrer, B., Gottlieb, E., Harris, R. A., Gerber, D., Hirschey, M. D. and Cohen, H. Y. (2019) SIRT6 promotes hepatic beta-oxidation via activation of PPARα. Cell Rep. 29, 4127-4143.e4128. https://doi.org/10.1016/j.celrep.2019.11.067
  24. Pike, L. S., Smift, A. L., Croteau, N. J., Ferrick, D. A. and Wu, M. (2011) Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim. Biophys. Acta 1807, 726-734. https://doi.org/10.1016/j.bbabio.2010.10.022
  25. Samudio, I., Harmancey, R., Fiegl, M., Kantarjian, H., Konopleva, M., Korchin, B., Kaluarachchi, K., Bornmann, W., Duvvuri, S., Taegtmeyer, H. and Andreeff, M. (2010) Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J. Clin. Invest. 120, 142-156. https://doi.org/10.1172/JCI38942
  26. Sanyal, A. J. (2019) Past, present and future perspectives in nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 16, 377-386. https://doi.org/10.1038/s41575-019-0144-8
  27. Schafer, Z. T., Grassian, A. R., Song, L., Jiang, Z., Gerhart-Hines, Z., Irie, H. Y., Gao, S., Puigserver, P. and Brugge, J. S. (2009) Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461, 109-113. https://doi.org/10.1038/nature08268
  28. Schultz, J. R., Tu, H., Luk, A., Repa, J. J., Medina, J. C., Li, L., Schwendner, S., Wang, S., Thoolen, M., Mangelsdorf, D. J., Lustig, K. D. and Shan, B. (2000) Role of LXRs in control of lipogenesis. Genes Dev. 14, 2831-2838. https://doi.org/10.1101/gad.850400
  29. Shang, J. L., Ning, S. B., Chen, Y. Y., Chen, T. X. and Zhang, J. (2021) MDL-800, an allosteric activator of SIRT6, suppresses proliferation and enhances EGFR-TKIs therapy in non-small cell lung cancer. Acta Pharmacol. Sin. 42, 120-131. https://doi.org/10.1038/s41401-020-0442-2
  30. Shen, C., Jiang, Y., Lin, J., He, Y., Liu, Y. and Fang, D. (2023) SIRT6 reduces the symptoms of premature ovarian failure and alleviates oxidative stress and apoptosis in granulosa cells by degrading p66SHC via H3K9AC. Gynecol. Endocrinol. 39, 2250003. https://doi.org/10.1080/09513590.2023.2250003
  31. Shi, M. Y., Bang, I. H., Han, C. Y., Lee, D. H., Park, B. H. and Bae, E. J. (2020) Statin suppresses sirtuin 6 through miR-495, increasing FoxO1-dependent hepatic gluconeogenesis. Theranostics 10, 11416-11427. https://doi.org/10.7150/thno.49770
  32. Tasselli, L., Zheng, W. and Chua, K. F. (2017) SIRT6: novel mechanisms and links to aging and disease. Trends Endocrinol. Metab. 28, 168-185. https://doi.org/10.1016/j.tem.2016.10.002
  33. Vernia, S., Cavanagh-Kyros, J., Garcia-Haro, L., Sabio, G., Barrett, T., Jung, D. Y., Kim, J. K., Xu, J., Shulha, H. P., Garber, M., Gao, G. and Davis, R. J. (2014) The PPARα-FGF21 hormone axis contributes to metabolic regulation by the hepatic JNK signaling pathway. Cell Metab. 20, 512-525. https://doi.org/10.1016/j.cmet.2014.06.010
  34. Wong, V. W., Ekstedt, M., Wong, G. L. and Hagström, H. (2023) Changing epidemiology, global trends and implications for outcomes of NAFLD. J. Hepatol. 79, 842-852. https://doi.org/10.1016/j.jhep.2023.04.036
  35. Wu, X., Liu, H., Brooks, A., Xu, S., Luo, J., Steiner, R., Mickelsen, D. M., Moravec, C. S., Jeffrey, A. D., Small, E. M. and Jin, Z. G. (2022) SIRT6 mitigates heart failure with preserved ejection fraction in diabetes. Circ. Res. 131, 926-943. https://doi.org/10.1161/CIRCRESAHA.121.318988
  36. Xu, X., So, J. S., Park, J. G. and Lee, A. H. (2013) Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP. Semin. Liver Dis. 33, 301-311. https://doi.org/10.1055/s-0033-1358523
  37. You, Y. and Liang, W. (2023) SIRT1 and SIRT6: the role in aging-related diseases. Biochim. Biophys. Acta Mol. Basis Dis. 1869, 166815. https://doi.org/10.1016/j.bbadis.2023.166815
  38. Zhang, J., Li, Y., Liu, Q., Huang, Y., Li, R., Wu, T., Zhang, Z., Zhou, J., Huang, H., Tang, Q., Huang, C., Zhao, Y., Zhang, G., Jiang, W., Mo, L., Zhang, J., Xie, W. and He, J. (2021) Sirt6 alleviated liver fibrosis by deacetylating conserved lysine 54 on Smad2 in hepatic stellate cells. Hepatology 73, 1140-1157. https://doi.org/10.1002/hep.31418
  39. Zhong, X., Huang, M., Kim, H. G., Zhang, Y., Chowdhury, K., Cai, W., Saxena, R., Schwabe, R. F., Liangpunsakul, S. and Dong, X. C. (2020) SIRT6 protects against liver fibrosis by deacetylation and suppression of SMAD3 in hepatic stellate cells. Cell. Mol. Gastroenterol. Hepatol. 10, 341-364. https://doi.org/10.1016/j.jcmgh.2020.04.005
  40. Zhu, C., Huang, M., Kim, H. G., Chowdhury, K., Gao, J., Liu, S., Wan, J., Wei, L. and Dong, X. C. (2021) SIRT6 controls hepatic lipogenesis by suppressing LXR, ChREBP, and SREBP1. Biochim. Biophys. Acta Mol. Basis Dis. 1867, 166249. https://doi.org/10.1016/j.bbadis.2021.166249